Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
La investigación de controversias de Sustainalytics identifica a las empresas implicadas en incidentes y eventos que podrían afectar a sus accionistas, su entorno comercial o sus operaciones.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback